DiaSorin SpA
Joel Cowen has extensive work experience in various roles within the healthcare industry. Joel currently holds the position of Vice President, Commercial - Immuno at DiaSorin, a company they joined in 2018. Prior to this, they served as Vice President, Marketing and Sr. Director of Marketing at the same company.
Before joining DiaSorin, Joel worked at Abbott Molecular Inc. starting in 2007. Joel held multiple roles at Abbott, including Director of Marketing, Americas, where they successfully turned around an underperforming organization. Joel also served as Senior Manager, Contracts and Pricing, and Global Marketing Manager, where they managed the Molecular franchise for Oncology and drove new product launches.
Joel's earlier experience includes working at Abbott Diagnostics as an Operations Training Manager & Regional Product Manager, where they focused on sales training and downstream commercial sales. Before that, they worked at OraSure Technologies as an Account Manager, responsible for rapidly driving sales in the Midwest region. Joel also held positions at Scios, Bristol-Myers Squibb, and sanofi-aventis, gaining valuable experience in specialty sales and as a sales representative.
Overall, Joel Cowen has demonstrated their expertise in marketing, commercial operations, and sales within the healthcare industry throughout their career.
Joel Cowen earned a Bachelor of Science degree in Environmental Biology from Eastern Illinois University from 1991 to 1996.
This person is not in any offices
DiaSorin SpA
4 followers
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company's business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.